NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.35_2629
Abstract: tal response in stage IB/IIA demonstrates meaningful clinical benefit with MOGA in early stage MF pts previously treated with systemic therapies despite MAVORIC not being powered to determine treatment effect by disease stage. Sponsor: Kyowa… read more here.
Keywords: phase evaluation; response; trial phase; stage ... See more keywords
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.05.033
Abstract: BACKGROUND Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR). We studied its efficacy and tolerability in persistent or recurrent cervical cancer patients. METHODS Eligible… read more here.
Keywords: phase evaluation; treatment; brivanib; gynecologic oncology ... See more keywords
Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Sign Up to like & getrecommendations! Published in 2018 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2018.06.017
Abstract: OBJECTIVE To determine the efficacy of dalantercept, a soluble ALK1 inhibitor receptor fusion protein, in patients with persistent or recurrent ovarian carcinoma and related malignancies. METHODS Eligibility criteria included measurable disease, 1-2 prior cytotoxic regimens… read more here.
Keywords: evaluation dalantercept; phase evaluation; treatment; gynecologic oncology ... See more keywords